



EXPRESS MAIL NUMBER  
EL92378964US

RECEIVED #87  
DEC 05 2001  
TECH CENTER 1600/2900  
*Adhiman*  
*2/20/02*

<b>Response to Communication Paper # 6</b>  Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Application Number	09/582,964
	Title	Use of Serine Protease Inhibitors to Inhibit Pathophysiology and Neuropathology in a Host
	Filing Date	July 6, 2000
	First Named Inventor	Hoffman et al.
	Examiner	R. Travers
	Group Art	1617
	Attorney Docket No.	THUR001

Sir:

This Paper is responsive to the Communication of October 4, 2001.

In the Communication of October 4, 2001, the Examiner stated that newly submitted claims 26-42 were directed to invention that was distinct from the "constructively elected" invention. As such, these newly presented claims were withdrawn from consideration and the response that was filed with the newly submitted claims was deemed non-responsive.


**In response, the Applicant's submit herewith a Continuation Prosecution Application and respectfully request that newly submitted claims 26-42 be examined in light thereof.**

If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number THUR001.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: October 25, 2001

By:   
Bret Field  
Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

F:\DOCUMENT\THUR\001\response to communication.doc